Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
71 hedge funds and large institutions have $231M invested in Taro Pharmaceutical Industries Ltd. in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 71 → 71 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
21% less capital invested
Capital invested by funds: $294M → $231M (-$62.3M)
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$4.66M |
| 2 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$3.32M |
| 3 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$1.21M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$874K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$686K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.35M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.02M |
| 3 |
Renaissance Technologies
New York
|
-$1.37M |
| 4 |
Morgan Stanley
New York
|
-$1.26M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$786K |
TARO Hedge Fund Activity: Q4 2021 in Review
71 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2021, worth a combined $231M — down 21% from $294M a quarter earlier.
Fund positioning in TARO was balanced in Q4 2021: 7 funds opened new positions, 7 closed out, 18 added to existing stakes and 30 trimmed.
The largest buyer was Brandes Investment Partners, adding an estimated $4.66M. The largest seller was Royal Bank of Canada, cutting an estimated $2.35M.
- 71 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $231M of Taro Pharmaceutical Industries Ltd. stock for Q4 2021, down 21% quarter-over-quarter.
- 7 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2021 and 7 closed out, a net change of 0 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2021 was Brandes Investment Partners, an estimated $4.66M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2021 was Royal Bank of Canada, an estimated $2.35M sold.
Based on aggregated 13F filings for Q4 2021.